Johnson & Johnson

Explore the latest insights on Johnson & Johnson and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Johnson & Johnson’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.Explore the latest insights on Johnson & Johnson and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Johnson & Johnson's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Cutia Therapeutics Secures Macao Marketing Approval for CU‑40102 Topical Finasteride Spray – Completing Greater China Rollout in Androgenetic Alopecia
CompanyDrug

Cutia Therapeutics Secures Macao Marketing Approval for CU‑40102 Topical Finasteride Spray – Completing Greater China Rollout in Androgenetic Alopecia

Cutia Therapeutics (HKG: 2487) announced that CU‑40102, its topical finasteride spray, has been approved for marketing in Macao, China, for the treatment of androgenetic alopecia – extending the product's Greater…

Qilu Pharmaceutical Drops RMB 400 Million Equity Stake in TYK Medicines – But TY‑9591 Licensing and China Commercialization Deal Stays Alive

Qilu Pharmaceutical Drops RMB 400 Million Equity Stake in TYK Medicines – But TY‑9591 Licensing and China Commercialization Deal Stays Alive

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
FDA Approves J&J's IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab
CompanyDrug

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

CompanyLegal / IP

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

CompanyMedical Device

Johnson & Johnson Wins U.S. 510(k) Clearance for MONARCH QUEST 3 Software Update – Advancing Robotic Bronchoscopy Navigation and Targeting

Johnson & Johnson Secures FDA De Novo Authorization for OTTAVA™ – World's First Table-Integrated Robotic Surgical System
Medical Device

Johnson & Johnson Secures FDA De Novo Authorization for OTTAVA™ – World’s First Table-Integrated Robotic Surgical System

Johnson & Johnson Reports Q2 2026 Results with 6.6% Sales Growth, Raises Full-Year Guidance
Company

Johnson & Johnson Reports Q2 2026 Results with 6.6% Sales Growth, Raises Full-Year Guidance

Johnson & Johnson Secures FDA Approval for Dual Energy THERMOCOOL SMARTTOUCH SF Platform, First Single-Catheter Solution Combining Radiofrequency and Pulsed Field Ablation
CompanyMedical Device

Johnson & Johnson Secures FDA Approval for Dual Energy THERMOCOOL SMARTTOUCH SF Platform, First Single-Catheter Solution Combining Radiofrequency and Pulsed Field Ablation

CompanyDrug

J&J’s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line

Johnson & Johnson Secures Second NMPA Approval for Akeega in BRCA2-Mutated Metastatic Prostate Cancer Following AMPLITUDE Trial Success
CompanyDrug

Johnson & Johnson Secures Second NMPA Approval for Akeega in BRCA2-Mutated Metastatic Prostate Cancer Following AMPLITUDE Trial Success

Show More